Key facts
- Pelage’s last known valuation is $323.0M (Oct 2025).
- It has raised $150.8M; the latest was Accelerator/Incubator ($120.0M) in Oct 2025.
- Notable investors include GV, Novo Holdings, ARCH Venture Partners, Hawktail, Main Street Advisors — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Pelage
- ·The full record, as it builds
Funding rounds
No funding rounds for Pelage are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Pelage
Provider of regenerative medicines intended to develop clinical-stage treatments for hair loss grounded in stem cell biology. The company offers a topical small molecule program, clinical trials for androgenetic alopecia and other alopecia types, stem cell biology research, a regenerative medicine platform, and press-reported financing information, providing clients with advanced hair loss treatment programs.
- Sector
- Healthcare
- HQ
- Los Angeles, CA, United States
- Founded
- 2018
- Employees
- 10
- Website
- pelagepharma.com/
- Ownership
- Privately Held (backing)
Pelage doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pelage shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pelage in its N-PORT filings yet. We sweep new filings monthly.